Purpose: To determine if brain-derived neurotrophic factor (BDNF) has a neuroprotective effect against N-methyl-D-aspartate (NMDA)-induced cell death in retina. Methods: NMDA was injected into the vitreous of rat eyes. NMDA-induced neuronal death was measured by morphometric analyses on cell counts of ganglion cell layer cells and thickness of retinal layers. Also, we conducted additional experiment using retrograde labeling with a fluorescent tracer (Fluoro-Gold) for exact counting of retinal ganglion cells (RGCs). In addition, intravitreal glutamate levels were measured with the use of a high-performance liquid chromatography (HPLC) system. Results: Morphometric analysis of retinal damage in NMDA-injected eyes showed that BDNF could protect inner retinal cells from glutamate receptor-mediated neuronal death. Also, counts of RGCs labeled with a fluorescent tracer showed that BDNF could protect RGCs from glutamate receptor-mediated neuronal death. Furthermore, measurements of intravitreal glutamate levels indicated an increase in this excitatory amino acid in the vitreous after NMDA injection. Conclusions: Exogenous BDNF can protect inner retinal cells (possible RGCs and amacrine cells) from NMDA-induced neuronal death. However, increased intravitreal glutamate levels in response to NMDA-mediated neurotoxicity may augment retinal degeneration.
Introduction
this mechanism is hypothesized to at least partially explain why damage to neurons of the optic nerve results in death Several growth factors and neurotrophic agents are of RGCs. On the other hand, some investigations showed important for regulation of neuronal development and that RGCs receive BDNF mainly from intraretinal sources maintenance of the adult central and peripheral nervous [5] and retrograde BDNF cannot rescue RGCs in the long systems [15] . Brain-derived neurotrophic factor (BDNF) term [8] . Thus, although further studies are needed for supports survival of retinal ganglion cells (RGCs) exact identification of intraocular origin and physiologic [9, 10, 16, 20, 30] and has been shown to act as a targetrole for BDNF, it is hypothesized to play important roles in derived trophic factor [16] . Thus, it is likely that damage to the development and maintenance of retinal tissue. neural axons in the optic nerve may cause inadequacy of
The presence of TrkB, a high affinity BDNF receptor, target-derived trophic factors, and result in RGCs death. In also implies a potential of BDNF as a neuroprotective the pathogenesis of glaucoma and other optic neuropathies, factor against numerous ocular diseases such as glaucoma, ischemic retinal diseases and retinal degenerative diseases [2] . In a number of animal models of ocular diseases, from injuries such as light exposure [12] , ischemia [28] , 0006 -8993 / 00 / $ -see front matter © 2000 Elsevier Science B. V. All rights reserved. PII: S0006-8993( 00 )02887-0 retinal degeneration [13] and axotomy [10, 19, 26, 30] . Furride and tropicamide and a single dose of 5 ml of 40 mM thermore, BDNF is involved in regeneration of axotomized NMDA (total amount, 200 nmol) was injected into the retinal neurons [17, 26] and supports survival of RGCs in vitreous space. culture [9] .
The glutamate receptor-mediated neurotoxicity is re-2.3. Morphometric analysis garded as one important mechanism in the pathogenesis of neurodegenerative diseases [11, 14, 18, 23, 27, 29] . Indeed, in
Morphometric analysis was carried out in a manner a number of ocular diseases such as glaucoma [4], similar to that described previously [21] . Briefly, 7 days ischemia [3, 22, 24] and optic neuropathy [32] , elevated after NMDA injection, the animals were killed by intralevels of glutamate have been reported. Thus, elevated peritoneal overdose injection of pentobarbital, and the eyes glutamate concentrations are hypothesized to be a common were enucleated. Eyes were immersed in fixative solution pathway of visual threatening diseases and to be involved containing 2.5% glutaraldehyde and 2% paraformaldehyde in augmentation of neurodegenerative processes. As menin 0.1 M phosphate buffer (pH 7.4) for 24 h at 48C, tioned above, although BDNF has been regarded to followed by dehydration and paraffin embedding. Transpossibly be a neuroprotective drug against many ocular verse sections with a thickness of 3 mm were made of rat diseases [1], knowledge about its neuroprotective mecharetinas through the optic disc. The sections were stained nism in animal models of retinal damage is limited with hematoxylin and eosin and subjected to morphometric [13, 28, 30, 31] . In particular, there are no conclusive data analysis. The degree of NMDA-induced retinal neuronal about whether BDNF inhibits primary (and disease-spedeath was quantified by cell counts in the ganglion cell cific) damaging processes in neuronal lesions, or secondary layer (GCL) and by the thickness of the inner plexiform (and probably more extensive) neurodegenerative events.
layer (IPL) at 1.0 to 1.5 mm from the optic disc. Retrograde labeling was made in a manner similar to involved in neuronal cell death, including retinal neuronal that described by Sawada et al. [25] . Briefly, rats were cell death [11, 14, 18, 27] . Herein, we report that BDNF anesthetized with xylazine and ketamine and then the protects retinal neuronal cells from glutamate receptorheads were fixed in a stereotaxic apparatus. Fluoro-Gold mediated neurodegenerative damage.
(Fluorochrome, Englewood, CO, USA) was microinjected bilaterally into the superior colliculi of rats. Three days after Fluoro-Gold injection, the animals were killed by 2. Materials and methods intraperitoneal overdose injection of pentobarbital and the eyes were enucleated. Eyes were fixed with 4% parafor-2.1. Animals maldehyde. Retinas were divided into six radial cuts and removed from the sclera and mounted on slides. Analysis Experiments were performed on adult male Sprague for the number of Fluoro-Gold labeled RGCs was carried Dawley rats (6 weeks after birth) which were housed at out. Briefly, the regions for counting the number of RGCs room temperature on a 12-h light / 12-h dark cycle and were selected from two fields of the central area (1 mm which were given water and food ad libitum. The animals from the optic disc) and two fields of the peripheral area (4 were killed by intraperitoneal overdose injection of penmm from the optic disc) on each retinal cut from six radial tobarbital. All studies were conducted in accordance with cuts. Thus, in each eye, a total of 24 fields (12 fields from the ARVO Statement for Use of Animals in Ophthalmic the central areas and 12 fields from the peripheral areas) and Vision Research.
were examined for counting the labeled RGCs.
Animal models of glutamate receptor-mediated 2.5. Amino acid analysis neuronal death
At 0, 1, 3, 7 and 14 days following intravitreal injection NMDA was obtained from Sigma (St. Louis, MO, USA) of NMDA, the vitreous humor was collected by cutting the and BDNF was obtained from Regeneron Pharmaceuticals eye and the vitreous acidified with one-tenth volume of 4 (Tarrytown, NY, USA). Animal models were made in a N perchloric acid. Before amino acid analysis, the medium manner similar to that described by Morizane et al. [21] .
was neutralized with 2.5 M potassium carbonate, spun at Briefly, rats were anesthetized by intramuscular injection 10 0003g for 10 min at 48C [33] and the supernatant of xylazine (total 2 mg) and ketamine (total 5 mg). The fraction analyzed by a micro high-performance liquid pupil was dilated with drops of phenylephrine hydrochlochromatography (HPLC) system for automated analysis of amino acids using precolumn o-phthaladehyde derivatizathe mean numbers (6standard error) of GCL cells at 0, 3 tion and fluorescence detection (CMNA 1200 refrigerated and 7 days after injection of NMDA (200 nmol Results and 25.960.9, respectively. The differences between the number of GCL cells in PBS-and BDNF-injected eyes on 3.1. Morphometric analysis for neuroprotective effects of the seventh post-treatment day were statistically significant BDNF (P,0.0001, ANOVA), but not on day 0 (P50.5651) and day 3 (P50.3860) (Fig. 4) . In eyes that have undergone intravitreal injection of After pretreatments with intravitreal injection of BDNF, NMDA (200 nmol), significant cell loss in the GCL and the mean thickness (6standard error) of the IPL at 0, 3 and thinning of IPL were observed after 7 days, as described 7 days after injection of NMDA (200 nmol) was 36.261.6, previously [6] . In an effort to elucidate the neuroprotective 22.261.5 and 24.061.8 mm, respectively. In PBS-injected effects of BDNF against NMDA-mediated retinal damage, (control) eyes, however, the mean thickness (6standard we conducted morphometric analyses. At 2 days after error) of the IPL at 0, 3 and 7 days after injection of injection of 1 ml of BDNF (0. (Fig. 3) .
shows a statistically significant difference (P50.0092, After the pre-treatment with intravitreal BDNF (1 mg), ANOVA) (Fig. 7) . protect retinal neuronal cells from various injuries, includand P50.2269, respectively, at day 0, 1, 3, 7 and 14, ing light exposure [12] , ischemia [28] , retinal degeneration respectively, ANOVA). Furthermore, the mean (6standard [13] and axotomy [19, 26, 30] . In addition, because BDNF acts as a target-derived trophic factor [16] , damage in tered intravitreally 2 days before NMDA injection in the neural axons and resultant inadequacy of retrograde supply present study. In addition, intravitreal injection of BDNF of this neurotrophic factor may play a part in the neurode-(10 mg) results in inhibition in elevations of glutamate generative processes seen in glaucoma and other optic concentrations in the vitreous of eyes with retinal damage neuropathies. This is why BDNF is regarded as a potential including NMDA-mediated neurotoxicity. Similar findings neuroprotective drug against any ocular conditions, such as were previously obtained from the measurements of inglaucoma, ischemia, traumatic injury and retinal degeneratravitreal glutamate levels in eyes with chemically-induced tive diseases. In these diseases, elevated levels of glutaretinal ischemia [7] . So, despite these limitations of BDNF mate in the vitreous have been reported [3, 4, 22, 24, 32] , so as a candidate for a possible neuroprotective drug for it is quite possible that abnormal levels of glutamate result ocular diseases, inhibition of release and / or uptake in in more extensive and serious secondary damage in neural diseased retinas suggests an inhibitory effect against tissues. However, to our knowledge, there were no reports secondary neurodegenerative events, which are common in about the selective neuroprotective effects of BDNF many retinal diseases. against glutamate receptor-mediated secondary neurode-BDNF has been regarded as a target-derived trophic generation in retina. Our attempt is to examine the factor [16] . However, some investigators have shown that possibility that BDNF protects against retinal neuronal RGCs receive BDNF mainly from intraretinal sources [5] . damage from secondary neurodegenerative processes.
In addition, recently, Isenmann et al. have reported that Our morphologic studies demonstrated that injection of retrograde BDNF cannot rescue RGCs on the long term NMDA, a ligand for glutamate receptors related to neuro- [8] . Thus, these findings suggest that the retrograde nal cell death results in statistically significant cell loss in degeneration of RGCs after lesion of the optic nerve may the GCL and thinning of the IPL as described elsewhere be the results of the physical lesion inflicted to the nerve [6] , which is in agreement with a previous report [21] . In instead of deprivation from target-derived neurotrophic our previous study [6] , in NMDA-injected eyes, up-regfactors. Also, since intravitreal injection of BDNF is ulated expression of another neurotrophic factor, CNTF, effective for survival of RGCs in our present study, has been found in the retina. Our morphometric studies intravitreal or intraretinal BDNF may be essential for showed the neuroprotective effects of CNTF against RGCs rather than superior colliculi-derived BDNF. NMDA-induced retinal damages. Also, neuroprotective
In conclusion, we suggest that exogenous BDNF can effects of BDNF against the retinal neurotoxicity mediated protect retinal neuronal cells in the inner retinal layers by NMDA have been shown by our results in the present from glutamate receptor-mediated neuronal death, and that study. In the present study, we have conducted a series of this neurotrophic factor can be potentially a clinically experiments in an attempt to elucidate protective effects of useful drug for many retinal diseases. BDNF in NMDA-related retinal damage. Our morphometric analysis showed that intravitreal injection of BDNF (1 mg) results in less cell loss in the GCL and less thinning of Acknowledgements the IPL, but injection of BDNF (0.1 mg) does not. Interestingly, intravitreal injection of a larger amount (10 Supported in part by a Grant-in-Aid for Scientific mg) of BDNF does not seem to have a significant additive Research from the Ministry of Education, Science, Sports neuroprotective effect. Furthermore, an additional experiand Culture, from the Ministry of Health and Welfare of ment using retrograde labeling of RGCs with Fluoro-Gold Japan. showed that BDNF protects RGCs in the GCL from glutamate receptor-mediated neuronal death. Statistically significant protective effects of BDNF are seen at 7 days References after the NMDA treatment.
In the present study, intravitreal injection of BDNF was hypoxia compared to 1 h before [7] . Although we were experience in the previous study [7] , BDNF was adminisand the retina as sources of brain-derived neurotrophic factor for
